That creates more demand for the stock, which pushes it higher, which forces more shorts to buy the shares and so on and so on. Look at Ligand Pharmaceuticals Inc. (NASDAQ:LGND). The stock has had a big run this year, especially …
Ligand Pharmaceuticals Incorporated LGND is scheduled to report second-quarter 2016 results on Aug 4 before the market opens. In the last reported quarter, Ligand had posted a positive earnings surprise of 67.39%. Let’s see how things are …
In after-hours, the stock was up 13.67% at $1.58 ... Ligand Pharmaceuticals Inc. (LGND) has signed a license agreement with Sermonix Pharmaceuticals LLC for the development and commercialization of oral Lasofoxifene in the United …
If you'd invested in Ligand Pharmaceuticals (NASDAQ: LGND) on the first trading day of 2011 ... and drug discovery and manufacturing platforms underpins this millionaire-maker stock's impressive run. In 2011, the underlying annual …
Ligand Pharmaceuticals Inc. LGND is scheduled to report third-quarter 2017 results ... Quote Ligand’s shares have outperformed the industry so far this year. The stock has rallied 44.1% compared with the industry’s 3.9% increase. …
The post LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND) Files An 8-K Submission of Matters to a …
Ligand Pharmaceuticals Inc. LGND reported third-quarter 2017 adjusted earnings of ... Ligand’s shares have outperformed the industry year to date. The stock has soared 42.5% compared with the industry’s 2.7% increase. View photos Total …
For a hedged play on Ligand Pharmaceuticals (LGND), MarketIntelligenceCenter.com’s option-trade picking algorithms recommend the Feb 16, 2018 $135 covered call for a net debit in the $130.78 area. That is also the break-even stock
LGND) are all expected to be lower after their earnings are released Thursday. The movement of stock prices in the …